Literature DB >> 28295645

Ureteroenteric anastomotic revision as initial management of stricture after urinary diversion.

Greg E Gin1, Nora H Ruel2, Jaspreet S Parihar1, Jonathan N Warner1, Bertram E Yuh1, Jonathan Yamzon1, Timothy G Wilson3, Clayton S Lau1, Kevin G Chan1.   

Abstract

OBJECTIVE: To report our experience with ureteroenteric anastomotic revision as initial treatment of stricture after urinary diversion.
METHODS: An institutional review board-approved retrospective study was carried out. A total of 41 patients who underwent primary ureteroenteric anastamotic revision were identified between 2007 and 2015. Data analyzed included patient characteristics, type of diversion, estimated blood loss, operative time, change in renal function, length of stay, postoperative complications and time with nephrostomy/stent. Success of revision was defined as an improvement in hydronephrosis on radiographic imaging and/or reflux during pouchogram. Predictors of length of stay and complications were analyzed using analysis of covariance.
RESULTS: A total of 50 renal units were revised with a success rate of 100%. The median length of stay was 6 days (2-16 days). There were a total of 15 complications (one major, 14 minor) in 14 patients (33% 30-day complication rate). The most common were wound infection (n = 4) and arrhythmia (n = 4). Robotic revision (n = 5) had a median length of stay of 3 days (2-4) with no complications.
CONCLUSIONS: Primary ureteroenteric anastomotic revisions have an excellent success rate at an experienced center and might obviate the need for multiple interventions. Open revision is associated with mostly minor complications. Robotic revision might reduce the morbidity of open revision in select cases.
© 2017 The Japanese Urological Association.

Entities:  

Keywords:  anastomosis; complications; outcomes; stricture; urinary diversion

Mesh:

Year:  2017        PMID: 28295645     DOI: 10.1111/iju.13323

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  The use of indocyanine green during robotic ureteroenteric reimplantation for the management of benign anastomotic strictures.

Authors:  Ziho Lee; Matthew E Sterling; Aryeh Y Keehn; Matthew Lee; Michael J Metro; Daniel D Eun
Journal:  World J Urol       Date:  2018-09-18       Impact factor: 4.226

Review 2.  Robotic assisted reconstruction for complications following urologic oncologic procedures.

Authors:  Daisy Obiora; Hailiu Yang; Ronak A Gor
Journal:  Transl Androl Urol       Date:  2021-05

3.  Treating benign ureteroenteric strictures: 27-year experience comparing endourological techniques with open surgical approach.

Authors:  M J van Son; M T W T Lock; M Peters; E E Fransen van de Putte; R P Meijer
Journal:  World J Urol       Date:  2018-09-19       Impact factor: 4.226

4.  Perioperative and Functional Outcomes of Robot-assisted Ureteroenteric Reimplantation: A Multicenter Study of Seven Referral Institutions.

Authors:  Albert Carrion; Ahmed Aly Hussein; Daniel Eun; Abolfazl Hosseini; Josep Maria Gaya; Ronney Abaza; Xavier Bonet; Umar Iqbal; Randall A Lee; Ziho Lee; Matthew Lee; Carles Raventos; Oriol Moreno; Joan Palou; Alberto Breda; Fernando Lozano; Francesc Vigués; Enrique Trilla; Khurshid A Guru
Journal:  Eur Urol Open Sci       Date:  2022-01-03

5.  Successful Multidisciplinary Repair of Severe Bilateral Uretero-Enteric Stricture with Inflammatory Reaction Extending to the Left Iliac Artery, after Robotic Radical Cystectomy and Intracorporeal Ileal Neobladder.

Authors:  Mariangela Mancini; Alex Anh Ly Nguyen; Alessandra Taverna; Paolo Beltrami; Filiberto Zattoni; Fabrizio Dal Moro
Journal:  Curr Oncol       Date:  2021-12-29       Impact factor: 3.677

6.  Impact of radiation on the incidence and management of ureteroenteric strictures: a contemporary single center analysis.

Authors:  Clinton T Yeaman; Andrew Winkelman; Kimberly Maciolek; Mei Tuong; Perri Nelson; Chandler Morris; Stephen Culp; Sumit Isharwal; Tracey L Krupski
Journal:  BMC Urol       Date:  2021-08-04       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.